Should you exit your Marsh Mclennan (NYSE:MMC) and Kintara Therapeutics (NASDAQ:KTRA) positions after a build-up?


USD 7.70  1.16  13.09%   

Today we may see the proof that Marsh Mclennan would recover much slower from the current slip as its shares went up 0.50% to Kintara Therapeutics's 0.7049%. As many rational traders are trying to avoid healthcare space, it makes sense to go over Kintara Therapeutics a little further and understand how it stands against Marsh Mclennan and other similar entities. We are going to analyze some of the competitive aspects of both Kintara and Marsh.
Published over a month ago
View all stories for Kintara Therapeutics | View All Stories
By analyzing existing basic indicators between Kintara Therapeutics and Marsh, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Marsh with a short position in Kintara Therapeutics. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Kintara is to check how much profit was generated for every dollar of assets it reports. Kintara Therapeutics secures a negative usage of assets of -94.47 %, losing $0.94 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kintara Therapeutics shows how discouraging it operates for each dollar spent on its assets.

How important is Kintara Therapeutics's Liquidity

Kintara Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Kintara Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Kintara Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Kintara Therapeutics's total debt and its cash.

How does Kintara utilize its cash?

To perform a cash flow analysis of Kintara Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Kintara Therapeutics is receiving and how much cash it distributes out in a given period. The Kintara Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Johnson Laura L 1 of 100000 shares of Kintara Therapeutics subject to Rule 16b-3

Legal trades by Kintara Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Kintara insider trading alert for grant of options (right to buy) by Johnson Laura L 1, the corporate stakeholder, on 5th of July 2022. This event was filed by Kintara Therapeutics Inc with SEC on 2022-07-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Cash and Equivalents Breakdown

Lets now take a look at Kintara Therapeutics cash and equivalents. In accordance with the recently published financial statements, Kintara Therapeutics has 8.84 M in Cash and Equivalents. This is 98.92% lower than that of the Healthcare sector and 98.02% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 99.67% higher than that of the company. As for Marsh Mclennan we see cash and equivalents of 909 M, which is 103.3% higher than that of the Biotechnology

447.1 M
909 M
KTRA8.84 Million0.65
Sector447.12 Million32.76
MMC909 Million66.6

Possible November correction of Kintara?

The maximum drawdown is down to 60.32 as of today. Kintara Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Kintara Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Kintara Therapeutics volatility. Kintara Therapeutics is a potential penny stock. Although Kintara Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Kintara Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Kintara instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Takeaway

Whereas some companies under the biotechnology industry are still a bit expensive, Kintara Therapeutics may offer a potential longer-term growth to investors. To sum up, as of the 5th of October 2022, we believe Kintara Therapeutics is currently undervalued. It follows the market closely and projects below average chance of distress in the next two years. However, our actual 90 days 'Buy-vs-Sell' recommendation on the company is Strong Sell.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Kintara Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to